Antimicrobial and Cytotoxic Activities of Selected Hieracium L. s. str. (Asteraceae) Extracts and Isolated Sesquiterpene Lactones.
2022
Authors:
Milutinović, Violeta M.Matić, Ivana Z.
Stanojković, Tatjana P.
Soković, Marina
Ćirić, Ana
Ušjak, Ljuboš J.
Niketić, Marjan S.
Petrović, Silvana D.
Document Type:
Article (Published version)
,
© 2022 Wiley‐VHCA AG, Zurich, Switzerland
Metadata
Show full item recordAbstract:
Antimicrobial and cytotoxic activities were tested for dried MeOH extracts of Hieracium calophyllum (CAL), H. coloriscapum (COL), H. pseudoschenkii (PSE), H. valdepilosum (VAL) and H. glabratum (GLA) herbs (flowering aerial parts), their 2 sesquiterpene lactones (SLs) 8-epiixerisamine A and crepiside E, and dried CH2 Cl2 extract of H. scheppigianum (SCH) herb. In microdilution test, extracts showed activity on all tested microorganisms (8 bacteria, 10 fungi). The best effect was exhibited by SCH and CAL on Salmonella Typhimurium (MIC=1.7-2.5 mg/mL MBC=3.4-5.0 mg/mL), and SCH and VAL on Candida albicans (MIC=2.5 mg/mL MFC=5.0 mg/mL). SLs showed notable effect on all tested fungi Aspergillus ochraceus, Penicillium funiculosum, C. albicans and C. krusei (MIC=0.15-0.4 mg/mL MFC=0.3-0.8 mg/mL). In MTT test, extracts inhibited growth of all tested cancer cells (HeLa, LS174 and A549), with the best effect on HeLa (IC50 =148.1 μg/mL for SCH, and 152.3-303.2 μg/mL for MeOH extracts); both SLs were active against HeLa cells (IC50 =46.2 μg/mL for crepiside E and 103.8 μg/mL for 8-epiixerisamine A). Extracts and SLs showed good safety profile on normal MRC-5 cells.
Keywords:
Hieracium species; Antimicrobial activity; Cytotoxicity; Flowering aerial parts extracts; TerpenoidsSource:
Chemistry & Biodiversity, 2022, 19, 7, e202200326-Funding / projects:
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200007 (University of Belgrade, Institute for Biological Research 'Siniša Stanković') (RS-MESTD-inst-2020-200007)
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200043 (Institute of Oncology and Radiology of Serbia, Belgrade) (RS-MESTD-inst-2020-200043)
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200161 (University of Belgrade, Faculty of Pharmacy) (RS-MESTD-inst-2020-200161)
DOI: 10.1002/cbdv.202200326
ISSN: 1612-1872
PubMed: 35621325
WoS: 000807699400001
Scopus: 2-s2.0-85131363392
URI
https://onlinelibrary.wiley.com/doi/10.1002/cbdv.202200326http://radar.ibiss.bg.ac.rs/handle/123456789/5005